Pricing Log in Create free account

Equillium, Inc. (EQ) vs Neuraxis, Inc. (NRXS)

Equillium, Inc. and Neuraxis, Inc. are both Biotechnology companies. Equillium, Inc. and Neuraxis, Inc. are of similar size ($88.8M and $86.2M). Neuraxis, Inc. grew revenue faster over the last twelve months: 65.2% against 13.9%. Equillium, Inc. has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Equillium, Inc. leads on 10 and Neuraxis, Inc. on 5.

Valuation

Metric EQ NRXS Biotechnology median
P/E n/m n/m 10.26
P/S 3.65 13.79 9.18
P/B 2.67 10.89 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 2.44 12.23 8.98
Earnings yield (14.93%) (12.89%) (34.89%)
Free cash flow yield (13.40%) (7.88%) (24.52%)

Profitability

Metric EQ NRXS Biotechnology median
Gross margin 100.00% 85.56% 65.16%
Operating margin 0.00% (144.51%) 0.00%
Net margin 0.00% (159.01%) 0.00%
Free cash flow margin 0.00% (106.10%) 0.00%
Return on equity (58.98%) (153.96%) (50.12%)
Return on assets (50.68%) (98.96%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EQ NRXS Biotechnology median
Revenue growth (TTM) 13.89% 65.22% 6.26%
EPS growth (last fiscal year) (69.57%) 22.13% 29.88%
Revenue growth, 5-year CAGR — 13.08% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EQ NRXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 23.40 3.04 4.89
Net debt to EBITDA 1.29 0.64 1.01

Dividend

Metric EQ NRXS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EQ NRXS Biotechnology median
Market cap 88.78m 86.15m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack